NCT00696735
- Conditions
- Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
- Locations
-
- Emmanuel GYAN Tours, France
- Philippe COLOMBAT Tours, France
Clinical trial condition
Follicular Lymphoma
Explore clinical trials studying Follicular Lymphoma. Study availability and eligibility vary by location and protocol.
231 public trials
70 recruiting studies
Follicular Lymphoma trial results
NCT00085696
- Conditions
- B-cell Lymphoma, Follicular Lymphoma, Hemic and Lymphatic Diseases, +11 more
- Locations
-
- UCLA School of Medicine Los Angeles, California, United States
- Florida Cancer Specialists Fort Myers, Florida, United States
- Emory University Cancer Institute, Winship Cancer Institute Atlanta, Georgia, United States
- Georgia Cancer Specialists Marietta, Georgia, United States
NCT00393107
- Conditions
- Disease Attributes, Follicular Lymphoma, Hemic and Lymphatic Diseases, +12 more
- Locations
-
- Ospedale di Arezzo Arezzo, Italy
- Ospedale Maggiore di Milano Milan, Italy
- Ospedale Monteluce Perugia, Italy
- Ospedale di Pescara Pescara, Italy
NCT00140569
- Conditions
- Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
- Locations
-
- Groupe d'atude des lymphome de l'adulte Yvoir, Belgium
- Hôpital Henri Mondor Créteil, France
- Centre Léon Bérard Lyon, France
- Hôpital Saint Louis Paris, France
NCT04224493
- Conditions
- Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
- Locations
-
- Southern Cancer Center Mobile, Alabama, United States
- Arizona Oncology Associates - Tuscon-Rusadill Road Tucson, Arizona, United States
- TOI - Clinical Research Cerritos, California, United States
- UCSF Fresno Clovis, California, United States
Active, Not Recruiting
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +21 more
- Locations
-
- Alaska Oncology and Hematology ( Site 0037) Anchorage, Alaska, United States
- Banner MD Anderson Cancer Center ( Site 0040) Gilbert, Arizona, United States
- Banner MD Anderson Cancer Center - University Medical Center Phoenix-Medical Oncology ( Site 0036) Phoenix, Arizona, United States
- University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0008) Aurora, Colorado, United States
Active, Not Recruiting
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
NCT05665062
- Conditions
- CLL/SLL, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, +17 more
- Locations
-
- City of Hope Duarte, California, United States
- Roswell Park Buffalo, New York, United States
- Memorial Sloan Kettering Cancer Center New York, United States
- Cleveland Clinic Cleveland, Ohio, United States
Active, Not Recruiting
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
NCT04542824
- Conditions
- Chronic Disease, Diffuse Large B Cell Lymphoma, Disease Attributes, +25 more
- Locations
-
- Tohoku University Hoaspital Sendai, Miyagi, Japan
- Aichi Cancer Center Hospital Aichi, Japan
- NHO Nagoya Medical Center Aichi, Japan
- National Cancer Center Hospital East Chiba, Japan
Active, Not Recruiting
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT04663347
- Conditions
- Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Hemic and Lymphatic Diseases, +11 more
- Locations
-
- University of Alabama at Birmingham Birmingham, Alabama, United States
- Cedars-Sinai Medical Center Los Angeles, California, United States
- David Geffen School of Medicine at UCLA Los Angeles, California, United States
- University of California San Francisco San Francisco, California, United States
Active, Not Recruiting
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
NCT02339922
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +35 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States